The short version of somatotroph cell fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The first elections took place in January 1889 and the county council formally came into being on 1 April 1889. On that day its first official meeting was held at the old Shire Hall on Old Elvet in Durham, the courthouse (built 1811) which had served as the meeting place of the quarter sessions which preceded the county council. The first chairman of the council was John Lloyd Wharton, who was the Conservative Member of Parliament for Ripon (in Yorkshire); he had also been chairman of the Durham Quarter Sessions since 1871. Durham was the first county council to be controlled by the Labour Party, which won the most seats in 1919. In 1974, the county was redesignated as a non-metropolitan county under the Local Government Act 1972. As part of those reforms the county ceded territory in the north-east to the new county of Tyne and Wear and in the south-east to the new county of Cleveland, but gained the former Startforth Rural District covering the part of Teesdale south of the River Tees from the North Riding of Yorkshire, and Darlington was brought back under the county council's control. Until 1974, the lower tier of local government comprised numerous boroughs, urban districts and rural districts. The districts were also reorganised in 1974 into eight non-metropolitan districts: Chester-le-Street, Darlington, Derwentside, Durham, Easington, Sedgefield, Teesdale, and Wear Valley. In 1997, Darlington became a unitary authority, removing it from county council control.
The administration of President Álvaro Uribe (2002–2010) adopted the democratic security policy which included an integrated counter-terrorism and counter-insurgency campaign. The government economic plan also promoted confidence in investors. As part of a controversial peace process, the AUC (right-wing paramilitaries) had ceased to function formally as an organization . In February 2008, millions of Colombians demonstrated against FARC and other outlawed groups. After peace negotiations in Cuba, the Colombian government of President Juan Manuel Santos and the guerrillas of the FARC-EP announced a final agreement to end the conflict. However, a referendum to ratify the deal was unsuccessful. Afterward, the Colombian government and the FARC signed a revised peace deal in November 2016, which the Colombian congress approved. In 2016, President Santos was awarded the Nobel Peace Prize. The Government began a process of attention and comprehensive reparation for victims of conflict. Colombia shows modest progress in the struggle to defend human rights, as expressed by HRW. A Special Jurisdiction of Peace has been created to investigate, clarify, prosecute and punish serious human rights violations and grave breaches of international humanitarian law which occurred during the armed conflict and to satisfy victims' right to justice. During his visit to Colombia, Pope Francis paid tribute to the victims of the conflict.
==== Surfactins ==== As the name implies, surfactins are potent biosurfactants (surfactants produced by bacteria, yeast, or fungi), and they have been shown to reduce the surface tension of water from 72 to 27 mN/m at very low concentrations. Furthermore, surfactins are also able to permeabilize lipid membranes, allowing them to have specific antimicrobial and antiviral activities. Since surfactins are biosurfactants, they have diverse functional properties. These include low toxicity, biodegradability and a higher tolerance towards variation of temperature and pH, making them very interesting for use in a wide range of applications.
== Awards == Phillips has been honored by Paul Newman and by John F. Kennedy Jr. as one of America's most generous business leaders when EAS was honored in 1999 with a Newman's Own/George Award. The United States Junior Chamber of Commerce honored Phillips in January 2000 as one of the Ten Outstanding Young Americans. Phillips was also chosen to help carry the Olympic torch on its relay across the United States for the 2002 Winter Olympics in Salt Lake City. Bill Phillips has donated over $5 million to the Make-A-Wish Foundation. Over the past 20 years Bill Phillips has granted over 600 wishes to kids facing life-threatening medical conditions through the Make-A-Wish Foundation. All the proceeds that would have gone to Phillips from the sale of his book Body-for-LIFE were donated to the Make-A-Wish Foundation. Phillips was awarded with The Ernst & Young Entrepreneur of the Year Award in 1997. On June 24, 2014, Bill Phillips was inducted into the Fitness Hall of Fame along with Jack LaLanne, Arnold Schwarzenegger, and Jillian Michaels.
1993/3114) Education (Annual Consideration of Ballot on Grant-Maintained Status) (England) Order 1993 (S.I. 1993/3115) Registration of Births, Deaths and Marriages (Fees) Order 1993 (S.I. 1993/3116) Vocational Training (Tax Relief) (Amendment No. 2) Regulations 1993 (S.I. 1993/3118) Foot–and–Mouth Disease (Amendment) (No. 2) Order 1993 (S.I. 1993/3119) Civil Courts (Amendment No. 2) Order 1993 (S.I. 1993/3120) Income Support (General) Amendment (No. 4) Regulations 1993 (S.I. 1993/3121) Appointment of Judges as Arbiters (Fees) (Scotland) Order 1993 (S.I. 1993/3125) Insurance Companies (Switzerland) Regulations 1993 (S.I. 1993/3127) Act of Sederunt (Summary Suspension) 1993 (S.I. 1993/3128) Durham and Tyne and Wear (County and District Boundaries) (Variation) Order 1993 (S.I. 1993/3129) National Savings Bank (Amendment) Regulations 1993 (S.I. 1993/3130) National Savings Stock Register (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3131) Savings Certificates (Yearly Plan) (Amendment) Regulations 1993 (S.I. 1993/3132) Savings Certificates (Amendment) Regulations 1993 (S.I. 1993/3133) Severn Bridges Tolls Order 1993 (S.I. 1993/3135) Environmentally Sensitive Areas (Argyll Islands) Designation Order 1993 (S.I. 1993/3136) Merchant Shipping (Registration, etc.) Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/3137) Merchant Shipping (Registration of Ships) Regulations 1993 (S.I. 1993/3138) Combined Probation Areas (Suffolk) Order 1993 (S.I. 1993/3139) Mid Essex Community Health National Health Service Trust Dissolution Order 1993 (S.I.
Sources: en.wikipedia.org
== Cautions == Numerous warnings must be examined before melarsoprol treatment can be initiated. Prior to initiation, the following must be noted: glucose-6-phosphate dehydrogenase deficiency, kidney or liver disease, cardiac problems (high blood pressure, irregular beating of the heart or arrhythmias, any damage to the heart muscles and potential signs of heart failure), preexisting nervous system disorders, and any signs of leprosy. Routine laboratory testing is needed before and after melarsoprol initiation. Laboratory parameters for both therapeutic effects and toxic effects need to be evaluated. Blood analysis is used to detect the presence of trypanosomes. An evaluation of the cerebrospinal fluid via a lumbar puncture is also used to determine an individual's white blood count and level of protein. These are diagnostic criteria such that the presence of trypanosomes, an elevated white blood count greater than five per microliter, or a protein content greater than 40 mg are considered abnormal and initiation should be considered. Continuous cerebrospinal fluid evaluation should be repeated every six months for at least three years in individuals that have undergone melarsoprol treatment. To assess potential concerns related to toxicity, the following should be completed: a complete blood count, an assessment of electrolyte levels, liver and kidney function tests, and a urinalysis to detect the appearance, concentration and content of the urine. Melarsoprol should be given using glass syringes (if they can be reliably sterilized).
== As a histone tail modification == One of the most well known epigenetic mechanisms that proline isomerization plays a role in is the modification of histone tails, specifically those of histone H3. Fpr4 is a PPIase, in the FK507BP group, that exhibits catalytic activity at the proline positions 16, 30, and 38 (also written P16, P30, and P38 respectively) on the N-terminal region of histone H3 in Saccharomyces cerevisiae. Fpr4's binding affinity is strongest at the P38 site, followed by P30 and then P16. However the catalytic efficiency, or the increase in isomerization rates, is highest at P16 and P30 equally, followed by P38 which exhibits a very small change in isomerization rates with the binding of Fpr4. Histone H3 has an important lysine residue at the 36 position (also written K36) on the N-terminal tail which can be methylated by Set2, a methyltransferase. Methylation of K36 is key to normal transcription elongation. Due to P38's proximity to K36, cross-talk between P38 isomerization and K36 methylation can occur. This means that isomer changes at the P38 position can affect methylation at the K36 position. In the cis position, P38 shifts the histone tail closer to the DNA, crowding the area around the tail. This can cause a decrease the ability of proteins to bind to the DNA and to the histone tail, including preventing Set2 from methylating K36.
PRC military strategists view the first island chain as part of a cordon sanitaire by the US and its allies, intended to encircle the country and limit its strategic depth and maritime security. The first island chain is often cited as a natural barrier and perceived constraint to the PRC's access to the Pacific Ocean. Within the first island chain, the PRC's access to the South China Sea is viewed as crucial for its navy, as the Yellow Sea and East China Sea are considered too shallow for clandestine submarine operations. Control over Taiwan and its deeper eastern waters would provide the People's Liberation Army Navy's ballistic missile submarines with less detectable access to the wider Pacific where they would serve as an important component of a credible second strike capability for the PRC. According to a 2018 United States Department of Defense report to Congress, the People's Liberation Army's Anti-Access/Area Denial military capabilities aimed at the first island chain are its most robust. The report also stated that the People's Liberation Army Navy's ability to perform missions beyond the first island chain is "modest but growing as it gains experience operating in distant waters and acquires larger and more advanced platforms."
== Overshoot Day == The Global Footprint Network measures the ecological footprint of the world's nations versus each nation's biocapacity. From this it derives an Earth Overshoot Day, an aggregation of the "overshoot day" for each country. The overshoot day is the day that the nation's footprint exceeds its biocapacity. Measurements are made in global hectares (gha). In 2019, the group issued their analysis based on 2016 data. Overshoot days for 135 countries ranged from Qatar on 11 February to Kyrgyzstan on 26 December. Thailand's overshoot day is 28 August. Overshoot days for other ASEAN nations were: Singapore, 12 April; Brunei, 21 May; Malaysia, 1 June; Vietnam, 8 October; Laos, 9 November; Indonesia, 18 December; Myanmar, 25 December. The ecological footprint per person in Cambodia and the Philippines are less than global biocapacity constant (1.63 gha) and thus do not have an overshoot day.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.